Cardiovascular Adverse Events With Intravitreal Anti–Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials

IMPORTANCE: Systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) is a matter of debate and regular updates are necessary. OBJECTIVE: To evaluate systemic adverse events (SAEs) associated with intravitreal anti-VEGF drugs compared with non–anti-VEGF treatments in patien...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Ophthalmol
Autors principals: Ngo Ntjam, Nadège, Thulliez, Marie, Paintaud, Gilles, Salvo, Francesco, Angoulvant, Denis, Pisella, Pierre-Jean, Bejan-Angoulvant, Theodora
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2021
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050790/
https://ncbi.nlm.nih.gov/pubmed/33856414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2021.0640
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars